Alamar Biosciences partners with Abcam to drive understanding of the human proteome
Alamar selects Abcam as a key provider of antibody content for its propriety NULISA technology platform Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences research tools, today announced a strategic partnership […]
